Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
As World Alzheimer’s Month comes to a close, we reflect on some of the highlights from this year’s campaign
Each year, ADI hosts its Alzheimer University for emerging associations, aiming to equip new associations with the skills and knowledge needed to run a successful Alzheimer or dementia association.
The annual event brings together basic scientists, clinical researchers, early career investigators, clinicians and the care research community to discuss the latest developments and innovation in Alzheimer’s and dementia research.
Lecanemab represents the first antibody treatment for Alzheimer’s disease to have received traditional approval from the Food and Drug Administration in the US.
Her Royal Highness Princess Muna Al Hussein is the fourth global Ambassador of ADI, joining Queen Silvia of Sweden, Queen Sofia of Spain and the Luis Guillermo Solís Rivera, former President of Costa Rica.
With only a fifth of WHO Member States meeting their commitments to the Global Action Plan on dementia, urgent action is needed to address the escalating global dementia crisis.
ADI member Dementia Australia has developed an app to help support brain health and encourage more timely dementia diagnoses.
As ADI prepares to attend the G7 summit in Hiroshima, Japan, DY Suharya writes about the journey of making dementia a priority at the G7 summit.